Welcome to our dedicated page for Mdxhealth Sa SEC filings (Ticker: MDXH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The MDxHealth SA (MDXH) SEC filings page on Stock Titan provides centralized access to the company’s regulatory disclosures as a foreign private issuer. MDxHealth files annual reports on Form 20-F and current reports on Form 6-K under the Securities Exchange Act of 1934. These documents offer detailed information on its precision diagnostics business for prostate cancer and other urologic diseases, its financial condition, and material corporate events.
Form 20-F filings contain audited financial statements prepared under International Financial Reporting Standards (IFRS), along with sections on business description, risk factors, management’s discussion and analysis, and details of MDxHealth’s molecular diagnostic portfolio. For a company that derives revenue from clinical laboratory service testing and out-licensing of its DNA methylation platform and biomarkers, these annual reports are a key resource for understanding revenue composition, research and development spending, and acquisition accounting.
Form 6-K reports are used by MDxHealth to furnish press releases and interim reports, including quarterly and half-year financial results, acquisition announcements such as the Exosome Diagnostics transaction, amendments to earnout obligations related to the GPS prostate cancer business, management and board changes, and other significant updates. Some 6-K exhibits, such as interim reports, may be incorporated by reference into the company’s shelf registration statements on Form F-3, as noted in the filings.
On Stock Titan, MDXH filings are updated as they appear on EDGAR and are accompanied by AI-powered summaries that highlight the main points in complex documents. Users can quickly scan annual 20-F reports, interim 6-Ks, and related exhibits to identify information on MDxHealth’s precision diagnostics operations, risk disclosures, financing arrangements, and acquisition-related commitments, without reading each filing in full.
MDxHealth SA director Eric Bednarski filed an initial Form 3 reporting indirect holdings of 4,700,457 ordinary shares. These shares are directly owned by private investment funds managed by MVM Partners, LLC, where Bednarski is a managing member. He disclaims beneficial ownership beyond any pecuniary interest described in the footnote.
MDxHealth SA Chief Commercial Officer John Bellano filed an initial statement of beneficial ownership showing multiple share option awards over ordinary shares. The filing lists option grants from June 2019 through March 2025, with exercise prices ranging from 12.40 Euros to $1.47 per share and expirations between 2029-07-24 and 2035-04-11.
Several grants vest in three equal installments on each of the first three anniversaries of the grant date, while others vest upon the achievement of Company performance criteria evaluated by the Board of Directors at the end of specified performance periods. All positions are reported as held directly and relate to options, not current share trades.
MDxHealth SA director and Chief Executive Officer Michael McGarrity filed an initial ownership report showing his equity position in the company. The filing lists direct holdings of 95,000 Ordinary Shares and multiple share option awards over additional Ordinary Shares.
The options cover various grants that generally vest in three equal installments over three years or upon achievement of specified company performance criteria, with exercise prices ranging from €2.90–€14.90 and $1.47–$2.62, and expiration dates between 2029 and 2035. This Form 3 is a baseline disclosure and does not report new purchases or sales.
MDxHealth SA officer Joseph Sollee filed an initial Form 3 describing his holdings of share options over ordinary shares. The filing lists multiple option grants with varying exercise prices in euros and U.S. dollars, different vesting schedules including performance-based vesting, and expirations extending through 2035.
MDxHealth SA Chief Financial Officer Ron Kalfus reported his existing holdings of share options over ordinary shares. The positions span multiple grants from 2019 to 2025, with strikes set in Euros and U.S. dollars and expirations running from 2029 through 2035.
They include options over 75,000 ordinary shares at an exercise price of $2.62 expiring on June 22, 2034, and 100,000 shares at $1.47 expiring on April 11, 2035. Earlier grants at prices such as 12.40, 8.00, 13.75, 6.84 and 2.90 Euros generally vest in three equal annual installments or upon achieving specified performance criteria evaluated by the Board of Directors.
MDxHealth SA director Don M. Hardison reported initial holdings of company share options. He holds options to purchase 30,000 ordinary shares at $2.62 per share, granted on June 22, 2024 and vested in full at the following annual general shareholders' meeting, and options for 10,000 ordinary shares at $2.18 per share, granted on June 27, 2025 and vesting in full at the next annual general shareholders' meeting.
MDxHealth SA director Sanford Jay Siegel filed an initial ownership report showing compensation-related options, not a market trade. He holds options to purchase 10,000 ordinary shares at $2.18 per share, granted on June 27, 2025, vesting in full at the next-year annual general shareholders' meeting and expiring on June 27, 2035.
MDxHealth SA director Hilde Windels has filed an initial ownership report showing indirect holdings of share options in MDxHealth SA through Hilde Windels BV. The positions include options over 1,000 ordinary shares at €49.70 expiring on June 1, 2028 and 1,000 shares at €12.80 expiring on July 1, 2029. Additional grants cover 30,000 ordinary shares at $2.62 expiring on June 22, 2034 and 10,000 shares at $2.18 expiring on June 27, 2035. These options were granted in prior years and vest or vested in connection with annual general shareholders' meetings, and the reporting person disclaims beneficial ownership of securities held by Hilde Windels BV except to the extent of any pecuniary interest.
MDxHealth SA director Koen Hoffman filed an initial statement of beneficial ownership, detailing his existing share option holdings. He reports options over 1,000 and 2,000 ordinary shares at exercise prices of 49.70 Euros and 12.80 Euros, granted in 2018 and 2019 and already fully vested. He also reports options over 30,000 and 10,000 ordinary shares at exercise prices of $2.62 and $2.18, granted in 2024 and 2025. Part of these options are held indirectly through Ahok BV, where he owns 53.33%, and he disclaims beneficial ownership beyond his pecuniary interest.
MDxHealth presents an annual report highlighting continued losses, going concern uncertainty and reliance on key prostate cancer tests. As of December 31, 2025, the company had an accumulated deficit of $403.0 million, a 2025 net loss of $33.5 million and net cash outflows from operations of $2.2 million. Management expects further losses and notes that failure to raise capital could jeopardize its ability to continue as a going concern. A $100 million senior secured credit facility with OrbiMed, maturing in 2029, imposes revenue and liquidity covenants and is secured by substantially all assets. Revenue is concentrated in Confirm mdx and GPS mdx tests, which generated about 76% of 2025 revenue and depend heavily on Medicare and commercial reimbursement. The report also describes intense competition in molecular diagnostics, complex billing and reimbursement risk, extensive regulatory exposure, and the importance of MDxHealth’s patent portfolio and CLIA-certified laboratories.